Trial Profile
A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Aug 2019 Status changed from active, no longer recruiting to discontinued.
- 29 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Jun 2018 Planned primary completion date changed from 1 May 2018 to 1 Jun 2019.